Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conestat Alfa in the Prevention of Acute Ischemic Cerebral and Renal Events After TAVI
NCT05145283Phase 2Completed
- Sponsor
- University Hospital Basel
- Start
- Mar 2022
- Primary completion
- Jan 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of conestat alfa in ischemic stroke, acute kidney injury (AKI), sponsored by University Hospital Basel. Started Mar 2022; status: completed.
02
Drugs
conestat alfa
03
Conditions
ischemic strokeacute kidney injury (AKI)
Beyond the preview
Go deeper on NCT05145283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05145283.